Wayne State researcher receives $1.9 million grant to improve EPCs-based cell therapy for vascular diseases

Chunying Li, Ph.D., assistant professor in the Wayne State University School of Medicine's Department of Biochemistry and Molecular Biology, has secured his first R01 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to study the role and mechanism of the chemokine receptor CXCR2 in regulating new blood vessel formation, the so-called angiogenesis.

The five year, $1.9 million grant (1R01HL128647) titled "Chemokine Signaling in EPC Angiogenesis: A Role of Lysine Methylation," aims to provide valuable information and potential therapeutic targets for enhancing endothelial progenitor cells (EPCs)-based cell therapy for certain vascular diseases, as well as advance the field of chemokine receptor biology.

"Bone marrow-derived EPCs hold great promise in regenerative medicine for the treatment of chronic or currently incurable cardiovascular diseases," said Li. "In settings of tissue ischemia or endothelial damage, EPCs are mobilized from the bone marrow into the circulation and home into sites of vascular injury, where they differentiate into mature endothelial cells and repair endothelial damage. Impaired EPC mobilization and homing influence vascular homeostasis and compensatory angiogenesis, and patients with reduced EPC levels are at increased risk for cardiovascular events and death."

"Despite its clear therapeutic potential, the molecular mechanisms that control EPC mobilization, homing and differentiation into endothelial lineage still remain incompletely understood," Dr. Li added. This lack of understanding in EPC biology represents a critical barrier in shifting the current paradigm of regenerative therapy from transplantation-based approach to endogenous activation of EPC repairing mechanisms. "Our project aims to define a yet-unexplored role and molecular mechanisms of lysine methylation of the chemokine receptor CXCR2 by a histone methyltransferase SMYD1 in modulating EPC migration and angiogenesis."

"We are honored to have the importance of our work recognized with this NIH grant," Li said. "I think it speaks to the potential high impact of this research project since the mechanistic characterization of the SMYD1-catalyzed CXCR2 lysine methylation are likely to provide valuable information for enhancing EPC-based cell therapy for certain vascular diseases, as well as to fundamentally advance the field of chemokine receptor biology. New therapeutic methods may evolve from this highly innovative study."


Wayne State University


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling